About Dr. Isaac Eliaz
Learn more about Isaac Eliaz MD, MS, LAc, a physician-scientist, clinician, and innovator whose work has focused extensively on Galectin-3 and therapeutic apheresis.
Isaac Eliaz, MD, MS, LAc, is a practicing physician, researcher, and innovator , and a recognized leading expert in the field of Galectin-3 and therapeutic apheresis.
Dr. Eliaz has pioneered and advanced the integration of therapeutic apheresis within systems-based, integrative medicine for more than 15 years. His work bridges biomedical research with long-term clinical application across oncology, autoimmune disease, neurological conditions, and complex inflammatory states.
Dr. Eliaz has been researching Galectin-3 for over three decades, authored multiple peer-reviewed publications in the field of Galectin-3, inflammation, cancer, sepsis, and apheresis, and has received NIH grant support for research investigating extracorporeal approaches to inflammatory and immune-mediated conditions.
A recognized authority on Galectin-3 and therapeutic apheresis, Dr. Eliaz has led foundational research on the selective removal of circulating inflammatory mediators, including galectin-3, and its potential biological relevance in acute and chronic inflammation. He has developed and investigated new approaches in the field of therapeutic apheresis.
As a repeat presenter at International Society for Apheresis conferences since 2015, Dr. Eliaz brings perspective shaped by both innovation and sustained clinical observation. He has followed apheresis patients for over a decade at Amitabha Medical Clinic, supporting clinical evaluation of safety and outcomes within a systems-based, integrative care model across diverse patient populations.
Explore Dr. Eliaz’s Cutting Edge Research: Galectin-3 and Chronic Disease
Explore Galectin-3 Research and Publications
30 years of Galectin-3 Research
For over 30 years, Dr. Eliaz has studied Galectin-3 — a circulating protein that plays a critical role in immune signaling and tissue repair. What began as research into inflammatory pathways evolved into a deeper understanding of how elevated Galectin-3 contributes to chronic inflammatory and fibrotic processes.
Galectin-3 and Chronic Inflammation
Dr. Eliaz’s work helped establish that chronically high Galectin-3 levels contribute to persistent inflammation, immune dysregulation, and fibrotic damage across multiple organ systems. More importantly, he discovered that because Galectin-3 circulates in the bloodstream, it can be accessed and reduced through targeted apheresis.
From Research to Clinical Practice
This research moved beyond the lab and Dr. Eliaz co-authored multiple peer-reviewed published studies examining how apheresis-based therapies can lower circulating Galectin-3 — and observed in clinical practice how patients respond when this inflammatory driver is addressed.
Learn What Dr. Eliaz is Doing for the Developing Galectin-3 Apheresis Technology for Sepsis
How Eliaz Therapeutics Approaches this Root Cause
Dr. Eliaz and Eliaz Therapeutics are advancing this science with apheresis technology — including work in sepsis and critical care. That research is separate from care at the clinic.
Learn more about Eliaz Therapeutics
A key protein driving sepsis, cancer, heart disease, fibrosis, and kidney disease.
A Central Driver of Disease, Inflammation, and Fibrosis
Galectin-3 regulates immune response, inflammation, and tissue repair in response to stress and injury.
When Your Body’s Protection Turns Harmful
Elevated Galectin-3 shifts from a protective role to a driver of inflammation, contributing to life-threatening conditions such as sepsis, kidney disease, fibrosis, and cancer progression.
A Validated Target with No Approved Treatment Yet
Supported by 10,000+ studies, yet no approved treatment exists to remove Galectin-3.
Explore the many dimensions of Dr. Isaac Eliaz’s work across medicine, research, innovation, and healing by visiting dreliaz.org. Follow his work with Eliaz Therapeutics on bringing a solution to sepsis and sepsis-associated acute kidney injury in critical care while advancing the science of Galectin-3, therapeutic apheresis to address some of medicine’s most serious and challenging conditions.
